Status:

COMPLETED

China Salt Substitute Study

Lead Sponsor:

The George Institute

Collaborating Sponsors:

Fu Wai Cardiovascular Institute and Hospital

University of Auckland, New Zealand

Conditions:

Hypertension

Cardiovascular Diseases

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Cardiovascular disease is a leading cause of death and disability worldwide, and blood pressure is a leading determinant of this risk. To date, strategies for blood pressure lowering have focused on d...

Detailed Description

This randomised trial will clearly identify whether a low-sodium, high-potassium salt-substitute is a feasible means of lowering blood pressure in high-risk individuals in rural China. The randomised ...

Eligibility Criteria

Inclusion

  • Participant inclusion will be based upon the presence of:
  • A doctor-confirmed high risk of future vascular disease defined as a history of any one of:
  • Stroke or transient ischaemic attack
  • Hospitalisation for management of any acute coronary syndrome
  • Surgery or angioplasty for peripheral vascular disease
  • Treated diabetes and age 55 years or older
  • Systolic blood pressure \>160mmHg
  • Estimated daily sodium intake of 260mmol/24hrs (about 15g/24hrs of NaCl) or above and expectation that at least 50% of daily dietary salt intake can be replaced with the salt-substitute. This will be estimated through interview of the potential participant and the individual responsible for daily food preparation (if this is not the patient) using a structured questionnaire.
  • Provision of informed consent

Exclusion

  • Potential participants will be excluded if:
  • they are on potassium-sparing medication
  • there is an established history of significant renal impairment that would preclude the use of the salt-substitute in the opinion of the responsible physician.
  • there is any reason why either the salt-substitute or normal salt are definitely indicated or definitely contra-indicated.

Key Trial Info

Start Date :

May 1 2004

Trial Type :

INTERVENTIONAL

End Date :

September 1 2005

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT00145756

Start Date

May 1 2004

End Date

September 1 2005

Last Update

September 5 2005

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

The Institute for Medical Science of Mudangjiang

Mudanjiang, Heilongjiang, China, 157000

2

The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, China, 110000

3

The People's Hospital of YuXian

Yangquan, Shanxi, China, 045100

4

The Health Center of Fengbo,ShunYi District

Beijing, China, 101300